Cart
sales@molnova.com
LY2835219
CAS No. 1231929-97-7
LY2835219( —— )
Catalog No. M10915 CAS No. 1231929-97-7
LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 43 | In Stock |
|
| 10MG | 66 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 87 | In Stock |
|
| 100MG | 113 | In Stock |
|
| 200MG | 142 | In Stock |
|
| 500MG | 259 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY2835219
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
-
DescriptionLY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.(In Vitro):Abemaciclib reduces cell viability with the IC50 values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells. Abemaciclib shows inhibition on A375R1-4, M14R, and SH4R with EC50 values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC50 values of 395, 260, and 463 nM, respectively. Abemaciclib inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells.(In Vivo):Abemaciclib (45 mg/kg, p.o.) in combination with RAD001 causes a cooperative antitumor effect in HNSCC xenograft tumor. Abemaciclib (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model.
-
In VitroAbemaciclib reduces cell viability with the IC50 values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells. Abemaciclib shows inhibition on A375R1-4, M14R, and SH4R with EC50 values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC50 values of 395, 260, and 463 nM, respectively. Abemaciclib inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells.
-
In VivoAbemaciclib (45 mg/kg, p.o.) in combination with RAD001 causes a cooperative antitumor effect in HNSCC xenograft tumor. Abemaciclib (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK4| CDK6
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1231929-97-7
-
Formula Weight506.59
-
Molecular FormulaC27H32F2N8
-
Purity>98% (HPLC)
-
SolubilitySoluble in DMSO
-
SMILESCCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C3=CC4=C(N=C(C)N4C(C)C)C(F)=C3)C=C2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Patrick J. Roberts, et al. JNCI J Natl Y Inst (2012) 104 (6): 476-487.
molnova catalog
related products
-
Furanodiene
Furanodiene has anti-inflammatory and antioxidant activities, it is active against gram-positive bacteria and Candida albicans.The in vitro effects of Furanodiene were examined on two human breast cancer cell lines, MCF-7 and MDA-MB-231 cells.
-
CCT251545
CCT251545 is a potent, orally bioavailable inhibitor of Wnt signaling with IC50 of 5 nM, also is a potent and selective chemical probe for CDK8 and CDK19 with >100-fold selectivity over 291 other kinases; potently inhibits reporter-based readouts of basal WNT pathway activity in LS174T and SW480 cells in the absence of WNT ligand with IC50 of 23 and 190 nM, respectively.
-
BS-181 hydrochloride
BS-181 is a potent, selective CDK7 inhibitor with IC50 of 21 nM.
